Wegovy and Pregnancy 2026

1. Why Wegovy is contraindicated in pregnancy

The FDA label for Wegovy includes a contraindication for use during pregnancy based on findings from preclinical (animal) studies. Specifically:

• Animal embryo-fetal toxicity: In rats and rabbits, semaglutide administration during organogenesis caused increased early embryo loss, structural skeletal abnormalities, and visceral malformations. Effects occurred at semaglutide exposures below the maximum human therapeutic exposure based on AUC comparison.
• Growth restriction: Reduced fetal body weight was observed across multiple animal studies.
• Insufficient human data: The number of pregnancies exposed to semaglutide in clinical trials is too small to draw safety conclusions, and post-marketing surveillance data remain limited.

Given these findings + the availability of pregnancy-safe alternatives for weight and diabetes management, FDA classifies Wegovy use as “not recommended” throughout pregnancy.

2. The ≥2-month discontinuation window

The FDA label specifically recommends discontinuing Wegovy at least 2 months before a planned pregnancy. This window has two purposes:

1. Drug clearance:Semaglutide's 7-day elimination half-life means it takes ~5-7 weeks (5 half-lives) for systemic concentrations to fall below pharmacologically active levels.
2. Tissue redistribution: Beyond plasma clearance, semaglutide redistributes from albumin-bound tissue stores. The 2-month window adds a margin to account for slower tissue clearance.

Practical implication: if you and your partner are actively trying to conceive, stop Wegovy now. If conception is planned in 3-12 months, talk to your prescriber about a discontinuation date.

3. Semaglutide pharmacokinetics + clearance math

Semaglutide is one of the longest-lasting GLP-1 receptor agonists by design — its 7-day half-life is what makes weekly dosing possible. Pharmacokinetic profile:

• Elimination half-life: ~7 days
• Time to steady state: 4-5 weeks of weekly dosing
• Time to clear from system after last dose:
• 50% cleared by ~1 week
• 75% cleared by ~2 weeks
• ~95-97% cleared by ~5 weeks (5 half-lives)
• <1% remaining by ~7 weeks (7 half-lives)
• Protein binding: >99% — bound to albumin

The protein-binding and tissue distribution mean even after plasma levels drop, slow tissue release continues at trace levels. The 2-month rule conservatively accounts for this.

4. If you become pregnant on Wegovy

Unplanned pregnancy during Wegovy treatment requires immediate action but typically does NOT mean automatic adverse outcome:

1. Stop Wegovy immediately — do not take another dose.
2. Call your prescriber today — schedule urgent visit or telehealth call within 24-48 hours.
3. Confirm pregnancy — quantitative beta-hCG blood test if not yet confirmed.
4. OB/GYN referral — early prenatal care + likely reproductive endocrinology consultation given the exposure.
5. Discuss continuation vs other options— most inadvertent early exposures don't require pregnancy termination, but this is a discussion to have with your OB.

Limited human post-marketing data on semaglutide exposure during early pregnancy have NOT shown a clear pattern of birth defects when exposure is brief (1-2 cycles before discontinuation). The data are insufficient for full reassurance but suggest the baseline risk is the major driver, not the medication exposure.

5. Breastfeeding considerations

Wegovy is also contraindicated during breastfeeding per the FDA label. The reasoning:

• Animal studies showed semaglutide presence in rat milk
• Human breast milk excretion not directly studied
• Effects on the breastfeeding infant are unknown
• Effects on milk production are unknown

The clinical decision is risk-vs-benefit: without safety data, the conservative path is avoidance. If you are postpartum and want to restart GLP-1 therapy, the standard approach is:

• Wait until you have stopped breastfeeding
• Discuss timing with your OB/GYN and prescriber
• Restart at the starter dose (0.25mg weekly) — your tolerance has reset

6. Wegovy and fertility

Wegovy has no documented direct effect on fertility — neither improving nor impairing it pharmacologically. However, the weight loss it produces commonly improves fertility outcomes in patients with obesity:

• PCOS (polycystic ovary syndrome): Weight loss of 5-10% often restores ovulation in PCOS-related infertility. See our PCOS + GLP-1 page.
• Anovulatory infertility: Weight loss can restore regular cycles in patients with obesity-related anovulation.
• Male fertility: Modest improvement in sperm quality observed with weight loss; mechanism likely inflammation reduction and hormonal normalization.
• Pregnancy outcomes: Pre-pregnancy weight loss in patients with obesity reduces risk of gestational diabetes, hypertensive disorders, and pre-term birth.

The strategy: use Wegovy to lose weight, then discontinue ≥2 months before active conception attempts. Many patients see improved fertility outcomes specifically because of pre-conception weight loss.

7. All GLP-1s have the same pregnancy contraindication

The contraindication isn't specific to Wegovy — it's a class effect. As of 2026, all FDA-approved GLP-1 receptor agonists carry pregnancy contraindications:

• Semaglutide: Wegovy, Ozempic, Rybelsus
• Tirzepatide: Zepbound, Mounjaro
• Liraglutide: Saxenda (Victoza discontinued April 2024)
• Dulaglutide: Trulicity
• Exenatide: Byetta, Bydureon BCise

Discontinuation windows differ slightly based on half-life:

• Semaglutide (7-day half-life): ≥2 months before pregnancy
• Tirzepatide (5-day half-life): ≥1-2 months before pregnancy
• Liraglutide (~13-hour half-life): ≥1 week clearance
• Dulaglutide (5-day half-life): ≥1-2 months before pregnancy
• Exenatide ER (weekly): ≥2-3 months before pregnancy

For specific timing per drug, consult your prescriber. The generic principle holds: GLP-1 therapy and pregnancy don't mix.

8. Pregnancy-safe weight + diabetes management

For weight management during pregnancy

Pregnancy is generally NOT the time to actively pursue weight loss — even patients with obesity are guided toward limited weight gain (5-15 lb) per ACOG guidelines, not loss. Approaches:

• Registered dietitian-led prenatal nutrition counseling
• Structured prenatal exercise programs
• Continuous glucose monitoring (especially if gestational diabetes risk)
• Bariatric surgery patients: continue micronutrient supplementation

For diabetes during pregnancy

• Insulin: Decades of pregnancy safety data; first-line for pregnancy-related diabetes
• Metformin: Class B (better safety profile in pregnancy than GLP-1s); sometimes used for gestational diabetes
• Lifestyle intervention: Structured carbohydrate counting, blood glucose monitoring

9. Postpartum: when can you restart?

The decision to restart Wegovy postpartum depends on breastfeeding status:

• Not breastfeeding: Can restart 6 weeks postpartum (standard postpartum recovery) at the starter dose (0.25mg weekly).
• Breastfeeding: Wait until you have completely stopped breastfeeding, then restart at starter dose.
• Mixed feeding or weaning: Discuss with your prescriber — strict avoidance during any breastfeeding is the label recommendation.

Why restart at 0.25mg? Your tolerance to GLP-1 has reset during the discontinuation period. Starting at your previous maintenance dose risks severe GI side effects.

10. Frequently asked questions

Is Wegovy safe during pregnancy?

No. Wegovy is contraindicated during pregnancy per FDA label. Animal studies showed reproductive toxicity at exposures below the human therapeutic level — increased fetal loss, structural abnormalities, and growth changes. Human data are insufficient for safety conclusions. If you become pregnant on Wegovy, discontinue immediately and notify your prescriber.

How long before trying to conceive should I stop Wegovy?

The FDA label recommends discontinuing Wegovy at least 2 months before planned pregnancy. Semaglutide has a ~7-day half-life and takes approximately 5-7 weeks to fully clear systemically (5 half-lives). The 2-month window provides a safety margin. Discuss exact timing with your prescriber — earlier discontinuation may be appropriate based on individual factors.

Can I breastfeed while taking Wegovy?

No. Wegovy is contraindicated during breastfeeding. It is unknown whether semaglutide passes into human breast milk, but animal studies showed presence in milk. Given the pediatric safety unknowns and Wegovy's contraindication during pregnancy, breastfeeding mothers should not use Wegovy. If you are postpartum and want to start GLP-1 therapy, discuss timing with your prescriber.

What if I got pregnant while on Wegovy?

Discontinue Wegovy immediately and contact your prescriber. They will refer you to obstetrics for early prenatal care and likely reproductive endocrinology consultation. Most early-pregnancy exposures to semaglutide have not been associated with confirmed teratogenic outcomes in limited human reports, but the data are insufficient for reassurance. Your OB/GYN will assess fetal development through standard prenatal screening.

Are any GLP-1 medications safe in pregnancy?

No GLP-1 medication is currently FDA-approved or considered safe during pregnancy. All GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro, Rybelsus, Saxenda, Trulicity, Bydureon) carry similar contraindications. For pregnancy-related obesity or diabetes management, alternative treatments include lifestyle modification, structured prenatal weight management programs, and (for gestational diabetes) insulin therapy — which has decades of pregnancy safety data.

Will Wegovy affect my fertility?

Wegovy itself has not been shown to directly affect fertility. However, weight loss in patients with obesity often improves fertility outcomes — both for women (improved ovulation, especially in PCOS) and men (improved sperm quality). The catch: you cannot take Wegovy through conception or pregnancy. If you're actively trying to conceive, the recommended approach is to lose weight on Wegovy, then discontinue ≥2 months before active conception attempts.

• Editorial board reviewed
• CC BY 4.0 data
• FDA-source citations
• Affiliate disclosed

This guide is editorial and does not constitute medical advice. Pregnancy-related medication decisions must be made in consultation with your prescriber and OB/GYN. GLP1Zoom is affiliate-disclosed. Full disclaimer.